19.   Ganduri R, Peddapapireddigari J, Vurimindi H, Ramprakash. Stability indicating liquid chromatographic method for the simultaneous determination of olmesartan medoxomil and azelnidipine in combined tablet dosage form. Int J Pharma Sci Res. 2014;5:275–282.

20.   Patel JK, Patel NK. Validated stability-indicating RP-HPLC method for the simultaneous determination of azelnidipine and olmesartan in their combined dosage form. Sci Pharm. 2014;82:541–54.

21.   Ueyama E, Takahashi F, Ohashi J, Konse T, Kishi N, Kano K. Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions. J Pharm Biomed Anal. 2012;61:277–283.

22.   Kawabata K, Urasaki Y. Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2006;844:45–452.

23.   Guengerich FP, Sari MA, Brian WR, Iwasaki M, Bäärnhielm C, Berntsson P. Oxidation of Dihydropyridine Calcium Channel Blockers and Analogues by Human liver Cytochrome P-450 IIIA4. J Med Chem. 1991;34:1838–1844.

24.   ICH Guideline, Q1A (R2): Stability Testing of New Drug Substances and Products. Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf (Accessed 17 December 2019)

25.   ICH Guideline, Q2(R1): Validation of Analytical Procedures: Text and Methodology. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf. (Accessed on 12 January 2020).